《2003BTS癌性胸腔積液診治指南》內(nèi)容預(yù)覽

The discovery of malignant cells in pleural fluid and/or parietal pleura signifies disseminated or advanced disease and a reduced life expectancy in cancer patients.Median survival following diag-nosis ranges from 3 to 12 months and is depend-ent on the stage and type of the underlying malignancy. The shortest survival time is ob- served in malignant effusions secondary to lung cancer and the longest in ovarian cancer, while malignant effusions due to an unknown primary have an intermediate survival time.

Currently, lung cancer is the most common metastatic tumour to the pleura in men and breast cancer in women.Together, both malig-nancies account for approximately 50–65% of all malignant effusions (table 1). Lymphomas, tu-mours of the genitourinary tract and gastro-intestinal tract as a group account for a further 25%.Pleural effusions from an unknown primary are responsible for 7–15% of all malig-nant pleural effusions.

點(diǎn)擊下載完整版：《2003BTS癌性胸腔積液診治指南》